New antibody takes aim at Hard-to-Treat cancers in first human trial

NCT ID NCT06515613

Recruiting now Disease control Sponsor: Context Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called CTIM-76 in people with advanced ovarian, testicular, or endometrial cancers that have not responded to standard treatments. CTIM-76 is a bispecific antibody designed to attach to a protein called Claudin-6 on cancer cells and help the body's immune T cells destroy them. The study will first find the safest dose, then check if the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CTIM-76 (a bispecific antibody that targets Claudin-6 on cancer cells and engages T cells to attack them)

What this could lead to

If successful, this could point toward a new treatment option for people with certain advanced cancers that have stopped responding to standard therapy.

What could go wrong

This is a very early Phase 1 trial with only 156 participants, so the drug may not prove safe or effective. Side effects from T-cell engagement can be severe, and the cancer types studied are hard to treat.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrial carcinoma endometrium neoplasm malignant testicular germ cell tumor ovarian cancer ovarian carcinoma testicular cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CANCER PLATINUM-RESISTANT OVARIAN CANCER TESTICULAR CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Duke Cancer Institute
RECRUITING

Durham, North Carolina, 27710, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Fox Chase Cancer Center
WITHDRAWN

Philadelphia, Pennsylvania, 19111, United States
Gabrail Cancer Center
WITHDRAWN

Canton, Ohio, 44718, United States
John Theurer Cancer Center
TERMINATED

Hackensack, New Jersey, 07601, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10021, United States

Contact Email: •••••@•••••
Precision NextGen Oncology & Research Center
WITHDRAWN

Beverly Hills, California, 90212, United States
Providence Cancer Institute of Oregon
RECRUITING

Portland, Oregon, 97213, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
SCRI at Denver Health
RECRUITING

Denver, Colorado, 80218, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
SCRI at Mary Crowley
RECRUITING

Dallas, Texas, 75230, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
University College London Hospital
RECRUITING

London, United Kingdom

Contact Email: •••••@•••••
University of Arkansas Winthrop P. Rockefeller Cancer Institute
RECRUITING

Little Rock, Arkansas, 72205, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Vanderbilt-Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37232, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Women & Infants Hospital of Rhode Island
RECRUITING

Providence, Rhode Island, 02905, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••